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Multiple sclerosis (ms) is a chronic demyelinating neurological disease result-ing from the predominately T cell-mediated 
autoimmune destruction of oligodendrocytes which 
synthesise myelin.1 The disease affects women twice 
as often as men and symptoms usually present when 
patients are between 20 and 40 years old, which 
means that women of reproductive age are the most 
susceptible.1 Several disease-modifying drugs (DMDs) 
have been reported to reduce the frequency of clinical 
MS attacks and are prescribed with the intent of 
slowing disability progression; these medications 
include interferon (IFN)-β 1a and 1b, glatiramer 
acetate, natalizumab, mitoxantrone and fingolimod, 
with IFN-β and glatiramer acetate currently considered 
first-line therapies.1 Many newer agents are also being 
introduced, including tyrosine kinase inhibitors.2,3 
Unfortunately, recent evidence has emerged 
regarding the potential pregnancy-related adverse 
effects of DMDs.4 In general, DMD therapy is 
discontinued during pregnancy, although the actual 
risk of adverse effects occurring due to IFN-β and 
glatiramer acetate appears to be low.5 This report 
describes a pregnant woman who took IFN-β 
throughout her first trimester and subsequently 
developed severe placental complications.
Case Report
A 30-year-old gravida 2 para 1 woman presented to 
the Tawam Hospital, Al Ain, United Arab Emirates, in 
2013. She had been diagnosed with relapsing-remitting 
MS five years previously, after she had developed 
unilateral optic neuritis with frequent relapses. These 
symptoms had progressed two years later to epilepsy 
and left-sided haemiplegia and her MS was re-classified 
as secondary progressive MS. She was prescribed 
IFN-β 1a at a dose of 30 µg weekly as a lifelong 
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األدوية املغرية للمرض قد تؤدي إىل قصور املشيمة
مضاعفات حادة يف مشيمِة امرأٍة حامٍل ومصابٍة مبرض التصلب املتعدد
�صلطان حممد �صالح الدين و موزيبوني�صا بيجام
abstract: Disease-modifying drugs (DMDs) such as interferon (IFN)-β and glatiramer acetate are often prescribed 
to slow disability progression in patients with multiple sclerosis (MS). However, adverse pregnancy outcomes have 
been reported with these medications. We report the rare occurrence of severe placental complications in a 30-year-
old pregnant woman with MS who continued to take IFN-β during her first trimester. She presented at the Tawam 
Hospital, Al Ain, United Arab Emirates, in 2013 with early-onset fetal growth restriction. At 30 gestational weeks, 
she developed severe pre-eclampsia. The baby was delivered via emergency Caesarean section and was discharged 
at the age of two months. Continuation of IFN-β during pregnancy may have contributed to the development of 
placental insufficiency in this patient. Increased education regarding the risks of DMDs for pregnant patients with 
MS is very important to ensure successful pregnancy outcomes.
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امللخ�ص: يعترب عقاري البيتا انتريفريون وا�صيتات اجللتيمرات من االأدوية امل�صتخدمة الإبطاء االإعاقة يف مر�صى الت�صلب املتعدد، وهناك 
ت�صارب يف البيانات اخلا�صة بتاأثري هذه االأدوية علي احلمل، هذا تقرير حالة عن حدوث م�صاعفات �صديدة يف م�صيمة اأمراأة حامل يف 
2013م  العربية املتحدة عام  الت�صلب املتعدد، ح�رضت املري�صة مل�صت�صفى توام بالعني يف االإمارات  العمر م�صابة مبر�ض  الثالثني من 
مع نق�ض مبكر يف منو اجلنني، يف االأ�صبوع الثالثني من احلمل تعر�صت املراأة مل�صاعفات احلمل ومت توليد الطفل ب�صكل طارئ عن طريق 
العملية القي�رضية، ومت ترخي�ض الطفل بعد �صهرين، اإن ا�صتمرار تعاطي عقاقري املر�ض يف الثالثة �صهور االأوىل من احلمل اأّدى ذلك اإىل 
حدوث ق�صور يف امل�صيمة، يجب االإهتمام بتثقيف وتوعية املر�صى امل�صابني بالت�صلب املتعدد عن هذه املخاطر من اأجل نتائج ناجحة للحمل.
كلمات مفتاحية: الت�صلب املتعدد؛ انرتفريون بيتا؛ ا�صيتات اجللتيمرات؛ ت�صمم احلمل؛ تاأخر منو اجلنني؛ ق�صور امل�صيمة؛ تقرير حالة.
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prophylactic therapy as well as levetiracetam at a dose 
of 750 mg twice daily to control her epilepsy. In 2013, 
she conceived spontaneously; however, the medication 
was discontinued only at 13 gestational weeks after 
her first visit to an obstetrician. Levetiracetam was 
continued throughout her pregnancy.
During her pregnancy, the patient remained 
stable; however, a fetal ultrasound at 22 gestational 
weeks indicated that all fetal growth parameters had 
decreased. Severe early-onset fetal growth restriction 
(FGR) was diagnosed. The results of a detailed 
anatomic survey, karyotyping by amniocentesis and 
a virology screening test were normal. However, 
prenatal ultrasonography revealed that the fetus had 
an echogenic mildly dilated bowel [Figure 1], most 
probably due to ischaemia. A uterine artery Doppler 
ultrasound revealed high-resistance flow with early 
diastolic notching [Figure 2A] and an umbilical artery 
Doppler ultrasound showed absent end-diastolic flow 
[Figure 2B]. Additionally, the patient suffered from 
oligohydramnios. These findings were suggestive of 
placental insufficiency as the cause for early-onset 
FGR. The patient was subsequently monitored with a 
series of biophysical tests.
At 30 gestational weeks, the patient developed 
severe pre-eclampsia that was further complicated 
by HELLP (haemolysis, elevated liver enzymes and 
low platelets) syndrome. As a result, an emergency 
Caesarean section was performed and the patient 
was given full high-intensive care to manage the pre-
eclampsia, including magnesium sulphate infusions, 
serial monitoring of vitals and renal and respiratory 
function tests. Post-delivery, the patient had an 
uneventful recovery and was discharged eight days 
after the Caesarean section in stable condition with 
the advice to continue IFN-β as lifelong prophylactic 
therapy. In this case, the placenta was not sent for 
histopathology examination; it is recommended 
to do so in future cases. At birth, the female baby 
weighed 980 g and was admitted to the Neonatal 
Unit of Tawam Hospital. A physical examination did 
not reveal any malformations or abnormalities. The 
neonate required a postnatal course of surfactant for 
respiratory distress. She also required total parenteral 
nutrition initially but subsequently tolerated enteral 
feeds. She was discharged at the age of two months.
Discussion
There are four clinical types of MS, including 
relapsing-remitting MS, secondary progressive MS, 
primary progressive MS and progressive-relapsing 
MS. Generally, DMDs are recommended for patients 
who suffer from relapsing forms of MS, such as 
relapsing-remitting MS or secondary progressive MS 
with exacerbations; the prescription criteria include 
abnormal neurological examinations, several MS 
attacks and a high burden of disease as assessed by 
magnetic resonance imaging of the brain.1 The patient 
in the current case was an ideal candidate for DMDs 
as she was first diagnosed with relapsing-remitting 
MS, which then progressed to secondary progressive 
MS with permanent neurological complications. 
Hence, she was on lifelong prophylactic therapy with 
IFN-β 1a.
 
Figure 1: Prenatal ultrasonography of a pregnant 
woman with multiple sclerosis showing a fetus with a 
mildly dilated echogenic bowel.
 
Figure 2A & B: Doppler ultrasonography of (A) the uterine arteries revealing high-resistance flow with early 
diastolic notching (arrow) and (B) the umbilical artery showing absent end-diastolic flow in a pregnant woman with 
multiple sclerosis.
EDN = early diastolic notching; RT = right; AEDF = absent end-diastolic flow.
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Conclusion
This case describes severe placental complications in 
a pregnant woman with MS who continued taking 
IFN-β during her first trimester. The continuation 
of this DMD well into the period of full placental 
development may have contributed to the development 
of early-onset FGR and pre-eclampsia in this patient. 
However, further research into this issue is required 
to determine whether these factors are related. It is 
advisable that women who continue taking DMDs 
during their pregnancies should be followed-up 
closely to assess and prevent the development of fetal 
and maternal complications.
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In the current case, the patient was prescribed 
levetriacetam monotherapy to control her epilepsy 
during pregnancy. With levetriacetam, the risk of 
major congenital malformations is comparable with 
that of the non-epileptic population, indicating the 
relative safety of the drug.6 On the other hand, a 
systematic review reported that IFN-β exposure was 
associated with lower mean birth weight, shorter 
mean birth length and preterm birth, although the 
drug was not associated with increased risk of low 
birth weight infants (<2,500 g), Caesarean section 
delivery, congenital anomalies or spontaneous 
abortion.4 Due to the limited data regarding the effect 
of DMDs on pregnancy outcomes, women are advised 
to stop taking the drug either three months or at least 
one month prior to conception.7,8 Close follow-up 
is recommended for patients who continue taking 
DMDs during their pregnancies in order to assess 
and prevent the development of any fetal or maternal 
complications. Women with MS should be given more 
education regarding the risks of DMDs in pregnancy.
Extra-villous trophoblast (EVT) cells are fetal 
cells that invade the mother’s uterus, where they 
transform the spiral arteries into large vessels capable 
of conducting sufficient blood to the placenta.9 
Early trophoblast invasion is important for placental 
function and the extent of arterial transformation 
by the trophoblasts affects successful reproductive 
outcomes.9 Severe early-onset FGR overlapping with 
severe pre-eclampsia, as in the present case, is 
mainly associated with features of impaired maternal 
uteroplacental perfusion secondary to defective EVT 
invasion, which results in insufficient blood supply to 
the placenta.10,11 Placental histopathological findings 
generally reflect abnormal uteroplacental flow with 
secondary chronic fetal vasoconstriction and distal 
villous changes.11,12 Trophoblast invasion is controlled 
by the uterine natural killer cells (uNK cells), the most 
common uterine leukocyte.9,13
The efficacy of IFN-β in patients with MS is 
due to its immunomodulatory properties; the drug 
downregulates major histocompatibility molecules 
on antigen-presenting cells, inhibits proinflammatory 
cytokine levels, increases regulatory cytokine levels, 
inhibits T cell proliferation and limits the trafficking 
of inflammatory cells in the nervous system.1 These 
properties evidently oppose the effects of uNK cells.9,13 
The patient in the current case took IFN-β until the 
13th week of her pregnancy, which is when EVT 
invasion and placental development occurs.9 How-
ever, further research is required to determine whether 
DMDs are related to placental insufficiency. Studies 
using experimental animal models are recommended 
to assess the relationship between IFN-β and EVT 
invasion or placental development.
